Chidamide, an epigenetic regulatory drug, is the only orally administered subtype‐selective histone deacetylase (HDAC) inhibitor that regulates host immunity and tumor microenvironment and has a potential role in restoring resistance sensitivity as well as inhibiting metastasis and recurrence.12 This evidence concerns the gene HDAC9 and neoplasm.